Junshi Biosciences

Explore the latest insights on Junshi Biosciences and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Junshi Biosciences’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Explore the latest insights on Junshi Biosciences and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Junshi Biosciences' developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

MindRank Signs Exclusive Greater China Commercialization Deal With Sunshine Mandi for MDR‑001 – AI‑Designed Oral GLP‑1 Candidate in Phase III for Obesity, Worth Up to RMB 1.75 Billion
CompanyDeals

MindRank Signs Exclusive Greater China Commercialization Deal With Sunshine Mandi for MDR‑001 – AI‑Designed Oral GLP‑1 Candidate in Phase III for Obesity, Worth Up to RMB 1.75 Billion

MindRank announced an exclusive commercialization partnership with Sunshine Mandi Pharmaceutical, a subsidiary of 3SBio (HKG: 1530), for MDR‑001 — an AI‑designed, oral small‑molecule GLP‑1 receptor agonist independently developed by MindRank.…

NMPA Approves Lilly's Jaypirca (Pirtobrutinib) as First‑Line Monotherapy for CLL/SLL – Non‑Covalent BTK Inhibitor Completes Line‑of‑Therapy Progression in China

NMPA Approves Lilly’s Jaypirca (Pirtobrutinib) as First‑Line Monotherapy for CLL/SLL – Non‑Covalent BTK Inhibitor Completes Line‑of‑Therapy Progression in China

Sino Biopharmaceutical's CTTQ Partners With STADA on Pembrolizumab Biosimilar TQB3570 – Exclusive European License With Options Across Oncology and Immunology

Sino Biopharmaceutical’s CTTQ Partners With STADA on Pembrolizumab Biosimilar TQB3570 – Exclusive European License With Options Across Oncology and Immunology

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Company

Junshi Biosciences Reports 55% Drop in Q3 Revenues

CompanyDrug

Junshi Biosciences Launches PD-1 Inhibitor Tuoyi for Advanced NSCLC in China

CompanyDrug

Junshi Biosciences’ Tuoyi Approved for First-Line NSCLC Treatment in China

CompanyDeals

Junshi Biosciences Plans USD 572M Private Placement to Fund Drug R&D and Expansion

Company

Junshi Biosciences’ H1 2022 Financials Show Tuoyi Sales Growth Despite Revenue Drop

CompanyDrug

Junshi Biosciences Gets NMPA Go-Ahead for TAB009/JS009 Cancer Study

CompanyDeals

Hansoh Pharma Licenses GHDDI’s GDI-4405 for Global Development in COVID-19

CompanyDrug

Junshi Biosciences’ JunMaiKang Biosimilar Gets NMPA Approval Filing

Show More